The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
The novel coronavirus infectious disease ( COVID-19") induced by novel
coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic
risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically
recognized and has no effective drugs for treatment currently. Therefore, we will launch a
scientific project "The efficacy and safety of carrimycin treatment in 520 patients with
COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of
lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish
the criteria for clinical cure and the early predictive model of COVID-19 progression. The
primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation
resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of
treatment. The secondary efficiency outcomes and adverse events were observed.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing YouAn Hospital
Collaborators:
Chinese Academy of Medical Sciences First Affiliated Hospital Bengbu Medical College First Affiliated Hospital of Chongqing Medical University Huangshi Central Hospital Huangshi Central Hospital, China Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences Nanyang Central Hospital No.2 People's Hospital of Fuyang City Renmin Hospital of Wuhan University Shenyang Pharmaceutical University Shenyang Tonglian Group CO., Ltd Shenyang Tonglian Group Co., Ltd. The Second Affiliated Hospital of Harbin Medical University The Sixth People's Hospital of Shenyang